Teri Willey is Managing Director and Officer of Pathway to Cures, the venture philanthropy fund created by the National Bleeding Disorders Foundation to accelerate the development of cures and therapies across all inheritable blood and bleeding disorders.

She joined the team in November 2022 to launch, lead and manage the new National Bleeding Disorders Venture Fund, LLC. The Fund us focused on equity investments in companies developing cures and therapies for inheritable blood and bleeding disorders. Teri also serves an advisor to Royalty Pharma, chair of the Oncode Institute International Advisory Board and a member of the Spinouts Denmark Advisory Board. Her personal investing efforts include a limited partnership in Sixty8 Capital and serving as an investing member of Portfolia funds.

Teri has been in the business of commercializing early-stage research results for nearly 40 years and in addition to the above was the founding managing director of IU Ventures’ Indiana Philanthropic Venture Fund, a senior executive for business development for Cold Spring Harbor Laboratory, Mount Sinai School of Medicine in NYC, founding chief executive of Cambridge Enterprise Ltd in Cambridge England and a co-founder of ARCH Development Partners an early-stage Midwest venture fund.

Her career has been about starting, reorganizing, and leading technology transfer programs, and launching new early-stage funds that invest in science-based ventures and underserved founders.

Willey briefed National Press Foundation fellows in November 2025: Rare Disease Funding Called ‘Modern-Day Civil Rights Issue.’ Check out the Rare Disease Reporting Guide.